Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Comprehensive Stroke Center Designations Could Decrease “Weekend Effect”

By HospiMedica International staff writers
Posted on 19 Sep 2011
A new study claims that stroke patients admitted on the weekend have higher death rates than those admitted on weekdays at many hospitals, but not at comprehensive stroke centers (CSCs).

Researchers at the at the University of Medicine and Dentistry New Jersey (UMDNJ; New Brunswick, USA) examined records of 134,441 stroke patients discharged from 88 private acute care hospitals in the state of New Jersey (USA) between 1997 and 2007. More...
Among these, 23.4% were admitted to one of 12 CSCs, 51.5% to one of 43 primary stroke centers, and 25.1% to one of 33 non-stroke centers. The researchers determined out-of-hospital mortality rates up to one year after admission.

The results showed that 28% of all stroke patients were admitted on the weekend, and that these patients had a significantly higher death rate (17.2%) within 90 days, when compared to patients admitted on a weekday (16.5%). After adjusting for patient demographics and coexisting conditions, the weekend effect represented a 5% difference in overall death rates. The researchers also found that although patients admitted after 2006 were 10 times more likely to receive intravenous (IV) thrombolysis treatment using analogs of tissue plasminogen activator (tPA), the "weekend effect" was still evident for stroke patients admitted to primary stroke centers or non-stroke centers. The study was published in the September 2001 issue of Stroke.

“The 'weekend effect' suggests patients admitted or treated during weekend hours will receive different care, have worse outcomes, which could account for several thousand US deaths,” said lead author James McKinney, MD, an assistant professor of neurology at UMDNJ. “Prior studies of the weekend effect have looked at in-hospital death rates and death rates right after discharge, but we wanted to look at longer outcomes after admission. We also wanted to determine if New Jersey's unique stroke center designations impacted patient treatment and outcomes.”

TPA is a serine protease found on the endothelial cells that line the blood vessels, and is also manufactured using recombinant biotechnology techniques. As an enzyme, it catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown. Because it works on the clotting system, tPA is used in clinical medicine to treat only embolic or thrombotic stroke. Use is contraindicated in hemorrhagic stroke and head trauma.

Related Links:

University of Medicine and Dentistry New Jersey






Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Surgical Headlight
IsoTorch
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.